News
Bevacizumab, Aflibercept Compared for Neovascular AMD
At the end of one year, likelihood of being weaned off treatment was higher for eyes treated with aflibercept versus bevacizumab
Your search for bevacizumab returned 23 results
News
Bevacizumab Biosimilar Alymsys Now Available
Alymsys is a vascular endothelial growth factor inhibitor.
News
Bevacizumab Biosimilar Vegzelma Gets FDA Approval
Vegzelma is a vascular endothelial growth factor inhibitor.
News
Diabetic Macular Edema Outcomes Compared for Aflibercept, Bevacizumab
Outcomes at 2 years comparable among patients with diabetic macular edema receiving aflibercept monotherapy, bevacizumab first
News
Bevacizumab Biosimilar Alymsys Gets FDA Approval
The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.
ESMO 2021, News
Pembrolizumab Plus Chemo ± Bevacizumab Prolonged Survival in Cervical Cancer
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
ESMO 2021, News
Adding Bevacizumab to Erlotinib Prolongs PFS in Non-Squamous Non-Small Cell Lung Cancer
There was no improvement in overall survival with bevacizumab.
Drugs in the Pipeline
Immunotherapy Combo Reduces Risk of Cancer Recurrence in Early-Stage Liver Cancer
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
News
Elahere Granted Accelerated Approval for Platinum-Resistant Ovarian Cancer
The approval was based on data from the SORAYA trial.
Drug Monograph Updates
October 2022 Recap of Drug Updates
The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of October. The chart below provides highlights of key monograph updates made this month (not an inclusive list). Click on the name of the drugs to view the full monographs on eMPR.com. Key: D=Dosing,…
